Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS006 in Mild to Moderate Ulcerative Colitis
NCT04074590Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of LYS006 in ulcerative colitis (UC), sponsored by Novartis. Started Feb 2020; status: terminated.
02
Drugs
LYS006
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04074590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074590.